Wire · opportunities
Owkin, Boehringer Ingelheim ink AI drug discovery deal
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Owkin and Boehringer Ingelheim entered a license agreement to use Owkin’s AI Scientist platform K Pro and multimodal patient data to accelerate drug discovery in oncology and immunology, expanding a previous pilot project.
This Wire brief tracks Boehringer Ingelheim, and It sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now leverage AI tools like Owkin’s K Pro to combine diverse patient data for deeper drug insights or speed up hypothesis testing. Companies ignoring AI in drug research risk falling behind in oncology and immunology innovation.
◆ Mentioned in this story
◆ Coverage
1 source · 2 Sep 2026
◆ Related on Wire
◆ Topics